Radiative neutron capture cross-section measurement of ge isotopes at n_TOF CERN facility and its importance for stellar nucleosynthesis

This manuscript summarizes the results of radiative neutron capture cross-section measurements on two stable germanium isotopes, 70Ge and 73Ge. Experiments were performed at the n_TOF facility at CERN via the time-of-flight technique, over a wide neutron energy range, for all stable germanium isotopes (70,72,73,74, and 76). Results for 70Ge [Phys. Rev. C 100, 045804 (2019)] and 73Ge [Phys. Lett. B 790, 458 (2019)] are already published. In the field of nuclear structure, such measurements allow to study excited levels close to the neutron binding energy and to obtain information on nuclear properties. In stellar nucleosynthesis research, neutron induced reactions on germanium are of importance for nucleosynthesis in the weak component of the slow neutron capture processes.Peer ReviewedArticle signat per 134 autors/autores: A. Gawlik, C. Lederer-Woods, J. Andrzejewski, J. Perkowski, U. Battino, P. Ferreira, F. Gunsing, S. Heinitz, M. Krtička, C. Massimi, F. Mingrone, R. Reifarth, A. Tattersall, S. Valenta, C. Weiss, O. Aberle, L. Audouin, M. Bacak, J. Balibrea, M. Barbagallo, S. Barros, V. Bécares, F. Bečvář, C. Beinrucker, E. Berthoumieux, J. Billowes, D. Bosnar, M. Brugger, M. Caamaño, F. Calviño, M. Calviani, D. Cano-Ott, R. Cardella, A. Casanovas, D.M. Castelluccio, F. Cerutti, Y.H. Chen, E. Chiaveri, N. Colonna, G. Cortés, M.A. Cortés-Giraldo, L. Cosentino, L.A. Damone, M. Diakaki, M. Dietz, C. Domingo-Pardo, R. Dressler, E. Dupont, I. Durán, B. Fernández-Domínguez, A. Ferrari, P. Finocchiaro, V. Furman, K. Göbel, A.R. García, T. Glodariu, I.F. Gonçalves, E. González-Romero, A. Goverdovski, E. Griesmayer, C. Guerrero, H. Harada, T. Heftrich, J. Heyse, D.G. Jenkins, E. Jericha, F. Käppeler, Y. Kadi, T. Katabuchi, P. Kavrigin, V. Ketlerov, V. Khryachkov, A. Kimura, N. Kivel, I. Knapova, M. Kokkoris, E. Leal-Cidoncha, H. Leeb, J. Lerendegui-Marco, S. Lo Meo, S.J. Lonsdale, R. Losito, D. Macina, T. Martínez, P. Mastinu, M. Mastromarco, F. Matteucci, E.A. Maugeri, E. Mendoza, A. Mengoni, P.M. Milazzo, M. Mirea, S. Montesano, A. Musumarra, R. Nolte, A. Oprea, N. Patronis, A. Pavlik, J.I. Porras, J. Praena, J.M. Quesada, K. Rajeev, T. Rauscher, A. Riego-Perez, P.C. Rout, C. Rubbia, J.A. Ryan, M. Sabaté-Gilarte, A. Saxena, P. Schillebeeckx, S. Schmidt, D. Schumann, P. Sedyshev, A.G. Smith, A. Stamatopoulos, G. Tagliente, J.L. Tain, A. Tarifeño-Saldivia, L. Tassan-Got, A. Tsinganis, G. Vannini, V. Variale, P. Vaz, A. Ventura, V. Vlachoudis, R. Vlastou, A. Wallner, S. Warren, M. Weigand, C. Wolf, P.J. Woods, T. Wright, P. ŽugecObjectius de Desenvolupament Sostenible::7 - Energia Assequible i No ContaminantPostprint (author's final draft

Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria.

BACKGROUND:Acute kidney injury (AKI) remains a treatment-limiting toxicity of colistin. Recently developed clinical practice guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) group have harmonized definitions of AKI, but have not been widely applied to patients receiving colistin. METHODS:We retrospectively defined AKI by KDIGO definitions among adult patients receiving intravenous colistin for ≥ 3 days. Risk factors for AKI within 48 hours and 7 days of initiating colistin were determined by multivariable logistic regression. RESULTS:Among 249 patients treated with colistin, rates of AKI were 12% and 29% at 48 hours and 7 days, respectively. At 48 hours, patients in the intensive care unit were at increased risk for AKI. Within 7 days, colistin daily doses >5mg/kg, chronic liver disease, and concomitant vancomycin were independent predictors. Seven percent of patients required renal replacement therapy at a median of 5 days (range: 3-7) following colistin initiation. CONCLUSION:Safe use of colistin is promoted by early detection of AKI with KDIGO criteria, avoiding nephrotoxins, and limiting duration of therapy

Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.

Rezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in the Phase 3 ReSTORE study based on the primary endpoints of day 14 global cure and 30-day all-cause mortality. Here, an analysis of ReSTORE data evaluating efficacy outcomes by baseline Candida species is described. Susceptibility testing was performed for Candida species using the Clinical and Laboratory Standards Institute reference broth microdilution method. There were 93 patients in the modified intent-to-treat population who received rezafungin; 94 received caspofungin. Baseline Candida species distribution was similar in the two treatment groups; C. albicans (occurring in 41.9% and 42.6% of patients in the rezafungin and caspofungin groups, respectively), C. glabrata (25.8% and 26.6%), and C. tropicalis (21.5% and 18.1%) were the most common pathogens. Rates of global cure and mycological eradication at day 14 and day 30 all-cause mortality by Candida species were comparable in the rezafungin and caspofungin treatment groups and did not appear to be impacted by minimal inhibitory concentration (MIC) values for either rezafungin or caspofungin. Two patients had baseline isolates with non-susceptible MIC values (both in the rezafungin group: one non-susceptible to rezafungin and one to caspofungin, classified as intermediate); both were candidemia-only patients in whom rezafungin treatment was successful based on the day 30 all-cause mortality endpoint. This analysis of ReSTORE demonstrated the efficacy of rezafungin for candidemia and IC in patients infected with a variety of Candida species

A new CVD diamond mosaic-detector for (n, ) cross-section measurements at the n_TOF experiment at CERN

At then_TOFexperimentatCERNadedicatedsingle-crystalchemicalvapordeposition(sCVD)Diamond Mosaic-Detectorhasbeendevelopedfor(n,α) cross-sectionmeasurements.Thedetector,characterized by anexcellenttimeandenergyresolution,consistsofanarrayof9sCVDdiamonddiodes.Thedetector has beencharacterizedandacross-sectionmeasurementhasbeenperformedforthe 59Ni(n,α)56Fe reaction in2012.Thecharacteristicsofthedetector,itsperformanceandthepromisingpreliminary results oftheexperimentarepresented

Rates of acute kidney injury by baseline (A) serum creatinine value and (B) creatinine clearance.

<p>Note (A). Rates of acute kidney injury were significantly higher for patients with a baseline serum creatinine value ≥1.01 mg/dL compared to ≤0.6 mg/dL at 48 hours (<i>P</i> = 0.01) and 7 days (<i>P</i> = 0.01).</p

Factors associated with colistin-induced Acute Kidney Injury (AKI).

<p>Factors associated with colistin-induced Acute Kidney Injury (AKI).</p